7 Baf-A1 solubility dmso versus 2.7 months, p = .0001) with maintenance docetaxel but, despite a 3-months improvement in median OS (primary endpoint), the difference did not reach statistical significance (12.3 vs. 9.7 months, p = .0853)[26]. Pemetrexed

versus placebo Patients with advanced NSCLC with a disease control after four learn more cycles of platinum-based therapy (not including pemetrexed) were randomized (2:1) to pemetrexed maintenance or placebo, until disease progression. A total of 663 patients were randomized and, among patients randomized to pemetrexed, 48% received more than 6 cycles of chemotherapy and 23% received more than 10 cycles. In the intent-to treat patient population, pemetrexed significantly improved both PFS (primary end point; HR = 0.50, 95% CI: 0.42 to 0.61, p < 0.0001; median PFS 4.3 and 2.6 months,

respectively) and OS (secondary end point; HR: 0.79, 95% CI: 0.65 to 0.5, p = 0.012; median OS 13.4 and 10.6 months, respectively) as compared with placebo [27]. A pre-specified analysis by histology was incorporated into the protocol showing consistent data with other recent studies using pemetrexed see more [28, 29]. In the non-squamous subgroup, pemetrexed strikingly improved PFS (HR = 0.44, 95% CI:0.36 to 0.55 median PFS 4.5 and 2.6 months, respectively) and OS (HR 0.70 95% CI: 0.56 to 0.88; p = 0.02, interaction p value 0.033) with a median survival advantage of 5 months (15.5 months versus 10.3 months). A significant delay in symptom worsening was observed on the pemetrexed arm especially for pain and hemoptysis. Erlotinib versus placebo Cappuzzo Dolutegravir price et al. evaluated the benefit of the EGFR tyrosine kinase inhibitor erlotinib as maintenance therapy in a phase III trial comparing erlotinib versus placebo, in patients who had not experienced disease progression

after four cycles of platinum-based therapy. The primary endpoints were PFS in the overall population and PFS in patients whose tumors had EGFR protein overexpression (as determined by immunoistochemistry – IHC). Patients assigned to erlotinib experienced a statistically significant improvement in PFS in both the intent-to treat (HR = 0.71 95% CI: 0.62 to 0.82 p < 0.0001; median 12.3 versus 11.1 weeks, respectively) and the EGFR IHC positive patient populations (HR = 0.69, 95% CI: 0.58 to 0.82; p < 0.0001). In the ITT population, patients assigned to the erlotinib arm experienced a statistically significant improvement in OS (HR = 0.81, 95% CI:0,70 to 0,95; p = 0.0088; median OS 12.0 versus 11.0 months, respectively). OS benefit was consistent across all patient subgroups; however, OS data for the EGFR mutation-positive population are highly censored and there was extensive crossover of EGFR-mutated patients assigned to placebo to EGFR TKIs in second-line therapy (16 of 24 patients, 67%). Patients who had stable disease after first-line chemotherapy seemed to have a more pronounced OS benefit with maintenance erlotinib (median 11.9 versus 9.